Physician profile
Brad S Friedmann
NPI 1922019363
$11,717.56
in general payments reported to CMS, 2019-2025
54 companies · $699 in 2025
The $699 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,931 · 2020: $1,860 · 2021: $2,348 · 2022: $1,710 · 2023: $1,371 · 2024: $1,798 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,867.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,430.31 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,048.15 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Pfizer INC. | $1,027.19 | 2019-2025 | |
| Lilly USA, LLC | $967.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $873.45 | 2020-2025 | |
| Amgen INC. | $753.65 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $619.02 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $546.98 | 2019-2024 | Verquvo, Lagevrio, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.09 | 2019-2024 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $298.44 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $264.51 | 2023-2025 | Rexulti |
| Allergan, INC. | $257.81 | 2019-2020 | |
| Exact Sciences Corporation | $231.97 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $225.50 | 2019-2022 | |
| Radius Health, INC. | $219.42 | 2019-2023 | Tymlos |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Friedmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.